COVID-19, community trials, and inclusion
- PMID: 33743853
- PMCID: PMC7972324
- DOI: 10.1016/S0140-6736(21)00661-9
COVID-19, community trials, and inclusion
Comment in
-
Inclusion and diversity in the PRINCIPLE trial.Lancet. 2021 Jun 12;397(10291):2251-2252. doi: 10.1016/S0140-6736(21)00945-4. Lancet. 2021. PMID: 34119064 Free PMC article. No abstract available.
Comment on
-
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.Lancet. 2021 Mar 20;397(10279):1063-1074. doi: 10.1016/S0140-6736(21)00461-X. Epub 2021 Mar 4. Lancet. 2021. PMID: 33676597 Free PMC article. Clinical Trial.
References
-
- Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313:1619–1620. - PubMed
-
- WHO . World Health Organization; Geneva: 2008. The World Health Report 2008—primary health care (now more than ever)
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
